SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2006
|Savient Pharmaceuticals, Inc.|
|(Exact Name of Registrant as Specified in Charter)|
|(State or Other Juris-
diction of Incorporation
|One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
|(Address of Principal Executive Offices) (Zip Code)|
|Registrants telephone number, including area code: (732) 418-9300|
|(Former Name or Former Address, if Changed Since Last Report)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On October 30, 2006, Savient Pharmaceuticals, Inc. (the Registrant) announced its financial results for the quarter and nine months ended September 30, 2006. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, on October 31, 2006, the Registrant held a publicly available live webcast discussion of its financial results for the quarter ended September 30, 2006. The transcript of the October 31, 2006 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
See Exhibit Index attached hereto.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|SAVIENT PHARMACEUTICALS, INC.|
|Date: November 2, 2006||By: /s/ Philip K. Yachmetz|
|Philip K. Yachmetz
Executive Vice President &
Chief Business Officer
|99.1||Press release dated October 30, 2006|
|99.2||Transcript dated October 31, 2006|